Literature DB >> 17479244

Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study.

B K Kilhovd1, A Juutilainen, S Lehto, T Rönnemaa, P A Torjesen, K F Hanssen, M Laakso.   

Abstract

AIMS/HYPOTHESIS: AGEs, modification products formed by glycation or glycoxidation of proteins and lipids, have been linked to premature atherosclerosis in patients with diabetes. We investigated whether increased serum levels of AGEs predict total, cardiovascular (CVD) or CHD mortality in a population-based study. SUBJECTS AND METHODS: Serum levels of AGEs were determined by immunoassay in a random sample of 874 Finnish diabetic study participants (488 men, 386 women), aged 45-64 years. These participants were followed for 18 years for total, CVD and CHD mortality.
RESULTS: Multivariate Cox regression models revealed that serum levels of AGEs were significantly associated with total (p = 0.002) and CVD mortality (p = 0.021) in women, but not in men. Serum levels of AGEs in the highest sex-specific quartile predicted all-cause (hazards ratio [HR] 1.51; 95% confidence intervals [CI], 1.14-1.99; p = 0.004), CVD (HR 1.56; 95% CI 1.12-2.19; p = 0.009), and CHD (HR 1.68; 95% CI 1.11-2.52; p = 0.013) mortality in women, even after adjustment for confounding factors, including high-sensitivity C-reactive protein. CONCLUSIONS/
INTERPRETATION: Increased serum levels of AGEs predict total and CVD mortality in women with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17479244     DOI: 10.1007/s00125-007-0687-z

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  40 in total

1.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

2.  N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins.

Authors:  S Reddy; J Bichler; K J Wells-Knecht; S R Thorpe; J W Baynes
Journal:  Biochemistry       Date:  1995-08-29       Impact factor: 3.162

3.  AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression.

Authors:  Eric Boulanger; Marie-Paule Wautier; Jean-Luc Wautier; Bernadette Boval; Yves Panis; Nicolas Wernert; Pierre-Marie Danze; Philippe Dequiedt
Journal:  Kidney Int       Date:  2002-01       Impact factor: 10.612

4.  Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy.

Authors:  Helen Vlassara; Weijing Cai; Jill Crandall; Teresia Goldberg; Robert Oberstein; Veronique Dardaine; Melpomeni Peppa; Elliot J Rayfield
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-12       Impact factor: 11.205

5.  Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease.

Authors:  B K Kilhovd; T J Berg; K I Birkeland; P Thorsby; K F Hanssen
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

6.  High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study.

Authors:  Bente K Kilhovd; Auni Juutilainen; Seppo Lehto; Tapani Rönnemaa; Peter A Torjesen; Kåre I Birkeland; Tore J Berg; Kristian F Hanssen; Markku Laakso
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-02-03       Impact factor: 8.311

7.  Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes.

Authors:  A M Schmidt; O Hori; J X Chen; J F Li; J Crandall; J Zhang; R Cao; S D Yan; J Brett; D Stern
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

Review 8.  Advanced protein glycosylation in diabetes and aging.

Authors:  M Brownlee
Journal:  Annu Rev Med       Date:  1995       Impact factor: 13.739

9.  Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry.

Authors:  Paul J Thornalley; Sinan Battah; Naila Ahmed; Nikolaos Karachalias; Stamatina Agalou; Roya Babaei-Jadidi; Anne Dawnay
Journal:  Biochem J       Date:  2003-11-01       Impact factor: 3.857

10.  Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products.

Authors:  J V Valencia; M Mone; C Koehne; J Rediske; T E Hughes
Journal:  Diabetologia       Date:  2004-05-01       Impact factor: 10.122

View more
  68 in total

1.  Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals.

Authors:  Michal Schnaider Beeri; Erin Moshier; James Schmeidler; James Godbold; Jaime Uribarri; Sarah Reddy; Mary Sano; Hillel T Grossman; Weijing Cai; Helen Vlassara; Jeremy M Silverman
Journal:  Mech Ageing Dev       Date:  2011-11-03       Impact factor: 5.432

Review 2.  Does accumulation of advanced glycation end products contribute to the aging phenotype?

Authors:  Richard D Semba; Emily J Nicklett; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-05-17       Impact factor: 6.053

3.  Inhibition of macrophage oxidative stress prevents the reduction of ABCA-1 transporter induced by advanced glycated albumin.

Authors:  Raphael de Souza Pinto; Gabriela Castilho; Bruno Alves Paim; Adriana Machado-Lima; Natalia M Inada; Edna Regina Nakandakare; Aníbal Eugênio Vercesi; Marisa Passarelli
Journal:  Lipids       Date:  2012-01-21       Impact factor: 1.880

4.  A receptor-based bioadsorbent to target advanced glycation end products in chronic kidney disease.

Authors:  Yangrong Zhang; Karen A Lapidos; Anca Gal-Moscovici; Stuart M Sprague; Guillermo A Ameer
Journal:  Artif Organs       Date:  2013-11-11       Impact factor: 3.094

5.  Serum carboxymethyl-lysine, disability, and frailty in older persons: the Cardiovascular Health Study.

Authors:  Heather E Whitson; Alice M Arnold; Laura M Yee; Kenneth J Mukamal; Jorge R Kizer; Luc Djousse; Joachim H Ix; David Siscovick; Russell P Tracy; Stephen M Thielke; Calvin Hirsch; Anne B Newman; Susan Zieman
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-10-14       Impact factor: 6.053

6.  Impaired osteogenic differentiation and enhanced cellular receptor of advanced glycation end products sensitivity in patients with type 2 diabetes.

Authors:  Mattabhorn Phimphilai; Peraphan Pothacharoen; Prachya Kongtawelert; Nipon Chattipakorn
Journal:  J Bone Miner Metab       Date:  2016-11-21       Impact factor: 2.626

Review 7.  Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms.

Authors:  Alin Stirban; Thomas Gawlowski; Michael Roden
Journal:  Mol Metab       Date:  2013-12-07       Impact factor: 7.422

8.  Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women.

Authors:  Richard D Semba; Luigi Ferrucci; Kai Sun; Justine Beck; Mansi Dalal; Ravi Varadhan; Jeremy Walston; Jack M Guralnik; Linda P Fried
Journal:  Aging Clin Exp Res       Date:  2009-04       Impact factor: 3.636

Review 9.  Advanced glycation end products (AGE) and diabetes: cause, effect, or both?

Authors:  Helen Vlassara; Jaime Uribarri
Journal:  Curr Diab Rep       Date:  2014-01       Impact factor: 4.810

10.  Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008.

Authors:  Markku Laakso
Journal:  Diabetes Care       Date:  2010-02       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.